Corey Cutler, MD, MPH, FRCP(C)

Dana-Farber Cancer InstituteBoston, Massachusetts - 02115 |
- CLINICAL TRIALS 3
- CONDITIONS3
- INTERVENTIONS8
- SINCE2006

Reduced Intensity Sequential Double Umbilical Cord Blood Transplantation Using Prostaglandin E2 (PGE2)
April 2009 - December 2011

Rituximab for Prevention of Chronic GVHD
September 2006 - January 2012

Campath in Chronic GVHD
July 2007 - January 2011
Neoplasms
Hematologic Neoplasms
Graft vs Host Disease
Melphalan
Rituximab
Fludarabine
Tacrolimus
Sirolimus
Antithymocyte Globulin
Ex-Vivo 16, 16 Dimethyl-Prostaglandin E2 Expansion
Alemtuzumab (Campath)



